
## FLEXIBLE STRENGTH. PROVEN SUCCESS.

Demonstrated long-term durable clinical outcomes in complex aortoiliac occlusive disease (AIOD) treatment through **5 years.** 

## Sustained clinical effectiveness through 5 years:

- 89.5% primary patency and 96.1% primary assisted patency per lesion<sup>1</sup>
- 89.1% freedom from target lesion revascularization (fTLR) per subject<sup>1</sup>

This physician-initiated study enrolled 59 patients from 3 participating centers with patients followed out to **5 years** and beyond.



Kaplan-Meier graph of primary patency with number of lesions at risk



## **DURABLE PATIENT BENEFIT VERSUS** BASELINE BEYOND 5 YEARS1

100% of patients improved ≥1
Rutherford category from baseline¹

improvement in mean resting ankle-brachial index (ABI) (P < .001, .95 mean ABI)<sup>1</sup>

3x improvement in median walking impairment questionnaire (WIQ) measures sustained beyond 5 years in long-term follow-up cohort<sup>1</sup>

	Preprocedure	3 years	5 years*
Walking distance	7 (N = 59)	25 (N = 39)	21 (N = 27)
Walking speed	3 (N = 59)	10 (N = 39)	9 (N = 27)
Stair climbing	3 (N = 50)	11 (N = 38)	9 (N = 27)

<sup>\*</sup> Median follow-up of 6.6 years.



## Reference

1. Holden A, Takele E, Hill A, et al. Long-term follow-up of subjects with iliac occlusive disease treated with the Viabahn VBX Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy. In press.



Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the market where this product is available.  $R_{x \, \text{only}}$ 

Products listed may not be available in all markets.

GORE, Together, improving life, VBX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2024 W. L. Gore & Associates, Inc. 231255064-EN MARCH 2024

